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Abstract – Nosocomial infection, in particular 
pneumonia, is an important risk factor for hospital 
mortality and morbidity. Acinetobacter baumannii is a 
common multi-resistant microorganism responsible of 
Ventilator Associated Pneumonia (VAP). Currently 
Colistin is a rescue therapy for this pathogen. The 
purpose of this study is to compare the outcome of 
VAP caused by Acinetobacter baumannii and VAP by 
other microorganisms in critical patients. 
Comorbidity, prognostic scores, mortality and 
eradication frequency did not turn out significantly 









I.  INTRODUCTION 
 
 
A nosocomial infection, also known as a hospital-
acquired infection or HAI, is an infection which 
development is favored by a hospital environment, such 
as one acquired by a patient during a hospital stay or one 
developing among hospital staff. Such infections include 
fungal and bacterial infections and are aggravated by the 
reduced resistance of individual patients [1]. 
In the United States, the Centers for Disease Control and 
Prevention estimate that roughly 1.7 million hospital-
associated infections, by all types of microorganisms, 
including bacteria, combined, cause or contribute to 
99,000 deaths each year [2]. In European hospital surveys, 
the category of Gram-negative infections is estimated to 
account for two-thirds of the 25,000 deaths each year. 
Nosocomial infections can cause severe pneumonia and 
infections of the urinary tract, bloodstream and other parts 





Many HAI are difficult to fight against with antibiotics 
and antibiotic resistance is spreading among Gram-
negative bacteria that can infect people outside the 
hospital [3, 4]. 
VAP refers to a type of pneumonia occurring more than 
48–72 hours after endotracheal intubation. It is the most 
common nosocomial infection in the intensive care unit 
(ICU) with an incidence of 10–20% out of all 
mechanically ventilated patients. Its prevalence increases 
with the duration of mechanical ventilation. VAP also 
increases the risk of all-cause mortality by 2–2.5 times, 
compared to patients without VAP[5]. The crude VAP 
mortality has been reported to be 20–70%, and the 
mortality related could be as high as 50%. The 
development of VAP is associated with longer duration of 
mechanical ventilation, ICU stay, hospital stay and higher 
costs. 
Among the microorganism involved in the pathogenesis 
of VAP, Pseudomonas aeruginosa and Acinetobacter 
baumannii are the predominant species and, together with  
Methicillin-resistant Staphylococcus aureus, account for 
the highest related mortality [5]. 
Acinetobacter baumannii is a non-fermenting, Gram-
negative, aerobic coccobacillus found extensively in 
natural environments that has emerged as one of the most 
troublesome pathogens for health care institutions 
globally [6, 7, 8]. This microorganism is characterized by 
the rapid development of resistance to the majority of 
antimicrobials, including aminoglycosides, 
fluoroquinolones, and carbapenems [9,10,11,12,13,14]. In 
addition from its resistance profile, A. baumannii shows 
the ability to survive for prolonged periods throughout a 
hospital environment, thus potentiating its ability for 
nosocomial spread. As reported by reviews dating back to 
the 1970s, hospital acquired pneumonia is still the most 
common infection caused by this organism. However, 
more recently, infections involving the central nervous 
system, skin and soft tissue, and bone have emerged as 
highly problematic for certain institutions [15,16, 
17,18,19,20]. 
The emergence of A. baumannii strains resistant to all 
routinely tested antimicrobials has led to the necessary 
revival of Colistin, a polypeptide antibiotic also known as 
polymyxin E (limited in use because of its neuro- and 
nephrotoxicity). This positively charged antimicrobial 
peptide was discovered in 1947, originating from Bacillus 
polymyxa. It is thought to target the anionic LPS 
molecules in the outer cell membranes of Gram-negative 
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bacteria, leading to interactions between the inner and 
outer cell membranes, with associated lipid exchange, 
membrane disturbance, osmotic instability and eventual 
cell death [21]. 
In vitro Colistin has a broad spectrum of action against 
Gram-negative bacteria, including some strains resistant 
to penicillins, carbapenems, aminoglycosides and 
fluoroquinolones. However, Proteus mirabilis, 
Providencia spp., Serratia spp., Burkholderia cepacia and 
Stenotrophomonas maltophilia are naturally not 
susceptible to Colistin. There are two commercially 
available forms of Colistin: Colistin sulfate for oral and 
topical use and CMS for parenteral use (also known as 
sodium Colistin methanesulfonate or Colistin 
sulfomethate sodium) [22].  
Despite its extensive use against A. baumannii, Colistin-
resistant outbreaks are quite sporadic when compared 
with the widespread dissemination of resistance for other 
antibiotics, such as carbapenems. Recently, variation in 
the levels of 35 proteins between A. baumannii American 
Type Culture Collection (ATCC) strain 19606 and its in-
vitro-derived Colistin-resistant mutant, RC64 (Colistin 
minimal inhibitory concentration, 2 and 64 lg/mL, 
respectively), has been shown by differential proteomics. 
This included changes in the expression of outer 
membrane proteins, chaperones, translation factors, and 
metabolic enzymes in RC64. In addition, this strain 
showed impaired in vitro fitness and longer duplication 
times compared with the parental strain. Colistin 
resistance in Gram-negative bacteria is most commonly 
due to decreased binding to the bacterial outer membrane 
[23, 24]. 
The aim of this study was to find the incidence, mortality 
and etiology of VAP, Colistin efficacy and patients 
outcome to formulate an institutional antimicrobial policy. 
Such an approach of guided empirical antibiotic therapy 
has shown to decrease morbidity and mortality, duration 
of treatment and hospital stay, and has also helped reduce 




II.  METHODOLOGY 
 
 
 Study population 
 
 
This study was performed at the ICU of AOUP “Federico 
II”, a medical surgical ten-bed unit. We performed a 
retrospective analysis of prospectively collected data on 
all patients admitted to our ICU from 1st January 2011 to 
1st January 2012. The following data were collected for 
all patients: age, sex, risk factors, chest XR (CXR), body 
temperature, leukocyte count, creatinine, presence of 
sputum, microbiological results of non-bronchoscopic 
bronchoalveolar lavage (BAL), predicted mortality rate 
based on the Simplified Acute Physiology II Score 
(SAPSII), Sequential Organ Failure Assessment (SOFA) 
score at admission, SOFA at diagnosis, Glasgow Coma 
Scale (GCS), length of stay in ICU (LoS), time between 
admission and development of the pneumonia, days of 
mechanical ventilation (VM) and presence of hypotension 
(defined as arterial systolic pressure less than 90 mmHg 
despite adequate fluid resuscitation in the emergency 
department). CXR, body temperature, leukocyte count, 
creatinine, presence of sputum and results of mini-BAL, 
in particular, were obtained at 72h, at 7 days, at 28 days or 
until discharge. The outcome at 28 days or at discharge 
was classified as: healing, microbiological eradication or 
persistence and exitus. 
 
 
VAP diagnosis and etiology 
 
 
Diagnosis of Ventilator Associated Pneumonia (VAP) 
was defined as pneumonia that occurred more than 48 
hours after hospital admission and, according to 
international guidelines of the CDC in Atlanta, it was 
diagnosed by the finding of a new or progressive 
pulmonary infiltrate associated with at least two of the 
following criteria: fever > 38°C, leukocytosis > 11,000 
cells/mm
3
 or leucopenia < 4.000 cells/mm
3
, purulent 
respiratory secretions [25]. VAP was defined as 
nosocomial pneumonia in a patient with at least 48 hours 
of mechanical ventilator support. VAP was defined as 
‘‘early onset’’ or ‘‘late onset’’ depending on whether the 
infection occurred within the first 4 days of VM or later. 
The etiology of the pneumonia was established by 
isolation of the organism from blood cultures or by 
culturing the organism from endotracheal aspirates or 
mini-BALs. By etiology, VAP were divided into two 
groups: VAP caused by Acinetobacter baumannii 
(AbVAP group) and VAP caused by other 
microorganisms (VAP group). We have compared these 
two groups regarding: mortality, eradication, LoS and 






We reported antibiotic therapy, its duration, the posology 
and the possible reasons for the precocious termination of 
therapy. In particular, we have studied the data relating to 
the Colistin. It was used as salvage therapy in infections 
due to Acinetobacter baumannii carbapenem-resistant 
(XDR). The dosages used were 3mUI of MSM 
(Colistinmetate sodium) every 8 hours i.v..  
Renal function was monitored by daily measurement of 





 Statistical analysis between AbVAP group and VAP 
group was performed by an independent sample t test and 
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III.  RESULTS 
 
 
From January 2011 through January 2012, 338 patients 
were hospitalized in Intensive Care Unit of AOU Federico 
II University. A total of 22 patients (6,51%) developed 
nosocomial respiratory infections. 
All patients received mechanical ventilation (mean length 
was 14,6 ± 3,75 days).  
18 (82% of 22 patients) episodes were classified as VAP.  
Out of 18 patients investigated, 10 (56%) were male and 8 
(44%) were female. 
The mean age was 47,8 ± 21,7 years for AbVAP group 
and 69 ± 16,7 years for the VAP group.  
Ten (56%) episodes of VAP were due to Acinetobacter 
spp. and eight (44%) to different etiology (including P. 
Aeruginosa and Klesbiella pneumoniae). Five patients 
(50%) belonging to the AbVAP group developed early 
onset pneumonia. Conversely, with regard to the VAP 
group, early onset pneumonia arose in only two patients 
(25%).  
Severity of illness upon admission to the ICU was similar 
between the two groups. More in details, the SOFA score 
was 4 ± 1,89 in AbVAP group vs. 4,7 ± 2,6 in VAP  
group. The SAPSII score was 17,6 ± 6,36 in AbVAP 
group vs. 21,5 ± 11,5 in VAP group. 
The most notable finding was the SOFA score at 
diagnosis (3.7 ± 1.4 in AbVAP group vs. 6.9 ± 3.6 in 
VAP group; p<0.05). 
Risk factors incidence was similar: hypertension was 50% 
in AbVAP group vs. 80% in VAP group; diabetes had an 
impact of 20% in the first group and 50% in the second 
group. The mean duration of stay in ICU was 32,3 ± 17,4 
(AbVAP group) and 37,8 ± 14,5 (VAP group). 
The 28-day mortality was corresponding in both units 
(20% AbVAP vs. 30% VAP). The treatment was based on 
Colistin (CMS= 3mUIx3/die); the mean duration of 
therapy was 14.6 ± 3.75 days; the frequency of 
eradication was 6/10 in the group AbVAP and 6/8 in VAP 
group (not statistically significant).  
Premature end of therapy for renal failure cases was not 
observed. 
Data are presented in Table 1. 
 
 
IV.  DISCUSSION 
 
 
VAP is the most common infection in intensive care units 
(ICU); it contributes significantly to the morbidity and 
mortality of ICU patients, with an estimated incidence 
rate of 8% to 28%. 
In a previous review published by American Journal of 
Respiratory and Critical Care Medicine, Castre et al 
reported that more than 60% of VAP is caused by aerobic 
GNB. The predominant GNB were P. aeruginosa and 
Acinetobacter spp., followed by Proteus spp., Escherichia 
coli, Klebsiella spp., and H. influenzae.                                  
As in other studies, we found that the incidence of VAP is 
11% and 60% of cases is caused by Acinetobacter 
baumannii [5]. 
Knowledge of predictors for the isolation a certain 
pathogen in patients with the clinical diagnosis of VAP 
has important practical implications since it determines 
which patients should receive active antimicrobials 
against this organism. Previous studies identified several 
factors associated with the isolation of A. baumannii in 
respiratory samples of patients with lung infection: prior 
sepsis, previous antibiotic use, re-intubation, length of 
hospital stay before infection, length of mechanical 
ventilation before diagnosis, exposure to imipenem, and 
exposure to fluoroquinolones [26,27,28]. 
Despite somewhat different definitions of early-onset 
pneumonia, varying from <3 to <7 days [28,29,30], drug-
resistant pathogens were more frequently observed in the 
late-onset cases than in the early-onset cases. Previous 
studies have reported that late-onset VAP was more often 
caused by Pseudomonas aeruginosa, Acinetobacter 
species, methicillin-resistant Staphylococcus aureus, 
vancomycin-resistant enterococci, extended-spectrum b-
lactamase–producers, and multiresistant Gram-negative 
bacilli, whereas early-onset VAP was more often caused 
by Haemophilus influenzae, Streptococcus pneumoniae, 
methicillin-susceptible S. aureus, and Enterobacteriaceae 
[28]. Antibiotic use is one of the major determinants of 
the shift toward resistant strains [26].  
Caricato et al in a retrospective analysis performed at the 
intensive care unit of “A Gemelli Hospital” located in 
Rome, Italy, found that all Acinetobacter b. related 
pneumonia were “late onset”[31]. 
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Trouillet et al. identified several factors related to the 
acquisition of VAP due to MDR microorganisms: 7days- 
mechanical ventilation, prior antimicrobial therapy and 
the use of broad-spectrum antibiotics [32]. 
Similarly, Rios et al. identified hospitalization prior to 
VAP onset during 5 days and the use of prior 
antimicrobial therapy as risk predictors of VAP caused by 
MDR pathogens [33]. 
In our study we found a VAP incidence of 5% (18/338); 
10 out of 18 (56%) episodes of VAP were due to 
Acinetobacter spp. and eight (44%) to different etiology 
(including P. Aeruginosa and Klesbiella pneumoniae). 
Five patients (50%) belonging to the AbVAP group 
developed early onset pneumonia. Conversely, with 
regard to the VAP group, early onset pneumonia arose in 
only two patients (25%). In addiction we not found 
different distribution pattern of etiologic agents between 
early- and late-onset VAP. Notably we found particularly 
high rates of early onset AbVAP (5/10) but we think that 
this data are attributable to a misrecognized outbreak of A. 
baumannii. More in details 3 out of 5 episodes are 
temporally close. 
A number of variables have been identified as 
independent predictors of outcome of pneumonia 
including severity of illness, presence of organ 
dysfunction or failure, underlying diseases and 
comorbidities, and specific causative pathogens (MDR 
pathogens or not) [28,34]. 
Previous studies have identified severity of illness as risk 
factor for VAP. Different prognostic scoring systems are 
used in critical care, including the Therapeutic 
Intervention Scoring System, the Mortality Predictor 
Model, the Simplified Acute Physiology Score, and the 
APACHE II, APACHE III, and APACHE IV scores. The 
value of the APACHE II, SOFA and CPIS scores in the 
prediction of mortality during VAP episodes was 
assessed. 
Gupta et al [28] in a prospective cohort study of 107 
patients observed that APACHE II score was an important 
parameter to stratify risk of developing VAP. A 
significantly higher value was observed in VAP group (P 
< 0.001).  
Garnacho-Montero et al. found that the severity of illness 
at the moment of pneumonia diagnosis measured by the 
SOFA scale is an independent predictor of fatality. 
Notably in the same study the autors have reported that 
the two groups of patients whose pneumonia was or was 
not caused by A. baumannii were similar with regard to 
severity of illness at admission measured by the APACHE 
II score [26]. 
We observed that the two arms of study were similar with 
regard severity of illness at admission measured by 
SAPSII score and SOFA score. However, we found the 
SOFA score determined at the time of VAP diagnosis to 
be increased among patients belong to VAP group. We 
believe that our data do not conflict with above-
mentioned studies because if scoring systems for severity 
of illness may be useful in stratify the risk of developing 
VAP, they do not have to correctly identify an AbVAP.  
The comorbidity analysis in our work is consistent with 
data obtained in other reports. We suggest that patients 
acquiring AbVAP are no more comorbid than patients 
that have VAP.  Similarly, in terms of comorbidities 
Garnacho-Montero et al not found significant difference 
between patients with and without AbVAP [26].  
Likewise, Gupta et al observed that the chronic illnesses 
were not more prevalent in VAP patients [28]. 
The most notable finding of the present study is that 
mortality rate does not differ between AbVAP group and 
VAP group.   
Should be emphasized that there is debate in the literature 
on the impact of Acinetobacter species infection on crude 
and attributable mortality. Intuitively, one could suppose 
that a pulmonary infection caused by multidrug resistant 
A. baumannii increases mortality. However, many 
variables are involved in the clinical course of critically ill 
patients.  
Fagon et al in a case-control study, for example, reported 
significantly higher mortality in cases of VAP caused by 
P. aeruginosa or A. baumannii [35].   
Similarly, Kollef et al. found that VAP due to non-
fermentative Gram-negative pathogens was an 
independent predictor of in-hospital mortality [36]. 
On the contrary, Garnacho-Montero used two different 
methods (case-control study and multivariate analysis) to 
demonstrate that episodes of pneumonia caused by 
multidrug resistant A. baumannii do not carry a worse 
prognosis than other causes of pulmonary infection in 
ventilated patients [26]. 
This finding is in agreement with a case-control study 
which concluded that VAP caused by A. baumannii was 
not associated with an increase in the risk of death, 
although imipenem-resistant episodes were associated 
with a tendency to higher mortality rates [37].   
There are various explanations for these apparently 
controversial findings: first, unspecific risk factors may 
not have been included in the matching process of case–
control and cohort studies (and thus differences in 
mortality may be attributed to these particular factors).  
Secondly, there are great differences in patient 
populations, methodological characteristics of the studies, 
proportions of patients who received appropriate 
empirical treatment, as well as factors associated with the 
pathogen itself, including genetic factors that lead to 
differences in virulence. 
At present, Colistin is rescue therapy for AbVAP. 
Potential therapeutic indications for Colistin have been 
restored and a number of studies have assessed its use in 
ICU with most commonly used regimens of 2MUI, 3MUI 
of CMS (Colistinmetate sodium) every 8 hours or 2.5-
5mg of Colistin base divided into 3 doses/die [38]. 
For example, Levin et al in a case series examined 59 
patients infected with P. aeruginosae and A. baumannii. 
Good clinical outcomes was obtained in 58% of cases; 
although the author found that the poorest results were 
observed in cases of pneumonia, compared with other 
types of infections [39]. 
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Garnacho-Montero et al evaluated patients with VAP due 
to A. Baumannii, with 21 episodes caused by 
microorganism susceptible exclusively to Colistin and 14 
susceptible to imipenem. The clinical cure, defined as 
remission of pneumonia symptoms was high (57%) [40]. 
Furthermore, in a study of 185 critically ill patients with 
Acinetobacter spp. or P. aeruginosa infections, 55 were 
treated with Colistin and 105 of the remaining 130 were 
treated with a carbapenem. Accordingly Reina et al.  
concluded that Colistin was as safe and effective as other 
antibiotics [41]. 
Finally, in a retrospective study, Rios et al compared 31 
patients with VAP caused by MDR Acinetobacter spp. or 
P. aeruginosa that preserve their susceptibility to 
carbapenems with 30 patients affected by VAP sustained 
by only-Colistin susceptible strains; he found that 
intravenous Colistin is effective [33].  
In our study all patients in AbVAP arm were treated with 
Colistin and the clinical resolution rate is 80%. Despite 
this finding, we observed a low bacteriological 
eradication rate (60%). These data are consistent with data 
reported by Garnacho-Montero in above-mentioned 
studies [40,26]. 
However, there are limited information on the 
pharmacokinetics of Colistin intravenous administration 
and its effectiveness for treatment of pneumonia because 
of its inadequate penetration in the lung parenchyma [38].  
With regard to the toxicity related to the use of Colistin 
we did not observe an increase of renal failure related to 
therapy. 
Considering the high mortality of VAP and low 
bacteriological eradication rate, nebulized Colistin has 
been employed  as an attempt to minimize systemic 
toxicity and improve drug deposition at the site of 
infection.  
Much of the data on inhaled Colistin originates from 
patients with cystic fibrosis (CF) who are colonized or 
infected with Pseudomonas aeruginosa. However, the 
literature is expanding outside this patient population. 
In a retrospective case series by Kwa et al., 18 of 21 
(86%) patients who received nebulized Colistin for 
hospital-acquired pneumonia caused by A. baumannii or 
P. aeruginosa (resistant to all antimicrobials except 
polymyxins) had favorable clinical and microbiological 
responses [42]. 
Similar, encouraging results were reported by 
Michalopoulos et al., who compared the outcomes for 8 
patients who received supplemental nebulized Colistin 
combined with parenteral antibiotics with those for 45 
patients who received parenteral Colistin only. Rates of 
clinical cure appeared superior with supplemental 
nebulized Colistin, but the patient numbers were small 
thus limiting statistical comparisons [43,44,45]. 
However, neither Food and Drug Administration (FDA) 
nor European Medicines Agency (EMEA) approved the 
use of inhaled Colistin form in non CF-Patients. 








We acknowledge that our study has some limitations, 
since it is a retrospective and mono-center analysis and 
the sample is relatively small. We cannot overlook the 
impact of the architectural design of the ICUs on the 
transmission of A. baumannii [46]. Third, it is well known 
that the incidence of multidrug resistant pathogens is 
closely linked to local factors and varies generally from 





V.  CONCLUSION 
 
 
VAP episodes caused by A. baumannii have a similar 
comorbidity, prognostic scores, mortality and eradication 
frequency to pneumonia episodes caused by other virulent 
pathogens. 
Colistin is a valid option for treating episodes of VAP due 
to carbapenem resistant strains and it should be used as 
first-line therapy for A. baumannii VAP if local 
epidemiological data show a high incidence for MDR 
strains. 
Even if in our study Colistin has 80% of healing, it is 
associated to 60% eradicated VAP episodes only. 
The pharmacokinetic-pharmacodynamics relationship of 
this antibiotic should be investigated further, in particular 
for inhalation use. In fact formulations for inhalation 
therapy are limited and minimal data support the high cost 
of such therapies. More data on efficacy and safety of 
inhaled antimicrobial therapy in specified populations of 
Translational Medicine @ UniSa, - ISSN 2239-9747 2012, 3(2): 15-21 
 
20 
Università degli Studi di Salerno 
patients with VAP are needed before such therapy could 
be recommended for routine clinical use. 
With regard to the toxicity related to the use of Colistin 
we did not observe an increase of renal failure related to 
therapy.  
Waiting for definitive data on Colistin and in the absence 
of new active drugs, strict application of prevention rule, 
as specified in the European HAP guidelines, is the only 
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